PT Industri Jamu Dan Farmasi Sido Muncul Tbk

sido

Overview

SIDO Overview

PT Industri Jamu Dan Farmasi Sido Muncul Tbk is an Indonesia-based company, which carries out business activities in herbal industry, such as medical industry (pharmacy), herbs, cosmetics, foods and beverages related to health, commerce, land transportation, services, wastewater treatment, plantation and printing. The Company's segments include Herbal medicine and supplement, Food and beverages and Pharmacy. The Company’s products include Tolak Angin Cair, Tolak Angin Anak + Madu, Tolak Angin Flu, Tolak Angin Sugar Free, Sido Muncul Tolak Linu, Kuku Bima Ener-G!, Susu Jahe, Kopi Jahe, Sido Muncul C-1000 (Dengan Ekstrak Lemon), Esemag, Sari Kunyit Soft Capsule, Tolak Angin Soft Capsule, Tolak Linu Soft Capsule, JSH Capsule, VCO Soft Capsule, Sido Muncul Vitamin D3 400 IU, Sido Muncul VItamin E 100 IU, Sido Muncul Vitamin E 300 IU, Minuman Madu dengan Jahe MADUSIDO, Tolak Angin Care, Tolak Linu Cool, Anak Sehat Rasa Anggur, Anak Sehat Rasa Coklat, and Anak Sehat Rasa Jambu Merah.

5101520ValueCompetitiveFutureFinancialsDividend
Exchange
Indonesia Stock Exchange

Symbol: SIDO

Main
Market Cap.
IDR 19.95Trillion

~$1.25B USD

Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Sector
Healthcare

Valuation

SIDO Valuation Metrics

665

IDR
0.0%

Closing Price on 2024-04-18

Price to Equity

20.99

P/E

At 20.99x P/E TTM, SIDO.JK is trading at a premium to its peers in the Pharmaceuticals & Health Care Research sector (avg 10.7x).

Price to Book

5.89

P/B

At 5.89x P/B TTM, SIDO.JK is trading at a premium to its peers in the Pharmaceuticals & Health Care Research sector (avg 1.1x).

Price to Sales

5.59

P/S

At 5.59x P/S TTM, SIDO.JK is trading at a premium to its peers in the Pharmaceuticals & Health Care Research sector (avg 0.7x).

Valuing PT Industri Jamu Dan Farmasi Sido Muncul Tbk based on its trailing twelve months (TTM) valuation metrics against its peers in the Pharmaceuticals & Health Care Research sector

Historical Price to Earnings

Other Valuation Metrics

Valuing PT Industri Jamu Dan Farmasi Sido Muncul Tbk relative to other stocks in the Pharmaceuticals & Health Care Research sector

Price/Cash Flow
18.90x
Price/Forward Earnings
18.32x
Enterprise Value/Revenue
5.36x
Enterprise Value/EBITDA
15.56x
PEG Ratio
-0.42x

Analyst Ratings

40
60
80
0
100

62.5

Undervalued

Fairly Valued

Overvalued

Last closing: IDR6652024-04-18
IDR 653.68

Fairly Close to Intrinsic Value: Analyst's intrinsic value is of SIDO is IDR654, which is 1% lower than SIDO's last closing price of IDR665 (as of 2024-04-18).

Valuation Recap of SIDO stock
WeightNotesScore
High
The P/E ratio is calculated by dividing the market price of a company's stock by its earnings per share (EPS). It is a key tool for investors and analysts to assess whether a stock is overvalued, undervalued, or fairly valued. A P/E ratio of 20.99x is above the ID market average of 8.46x and is trading at a premium to peers in the Pharmaceuticals & Health Care Research sector (10.68x). In fact, less than 25% of its peers trade at a higher P/E ratio than SIDO.

High
The P/B ratio is calculated by dividing the market price of a company's stock by its book value per share (BVPS). It measures the company's stock value relative to its assets minus liabilities. A P/B ratio of 5.89x is above the peers average of 1.15x in the Pharmaceuticals & Health Care Research sector. SIDO trades at a higher P/B ratio than >75% of its peers in the Pharmaceuticals & Health Care Research sector.

Medium
The P/S ratio is calculated by dividing the market price of a company's stock by its sales per share. It measures the company's stock value relative to its sales. A P/S ratio of 5.59x is above the peers average of 0.71x in the Pharmaceuticals & Health Care Research sector. When considered alongside the Forward Price/Earnings ratio, they serve to illustrate investors' expectations of SIDO's valuation relative to its current sales and future earnings growth. SIDO trades at a Forward P/E ratio of 18.32x, which is considered richly valued by analysts.

Low
The Price/Cash Flow ratio (P/CF) is calculated by dividing the market price of a company's stock by its cash flow per share. It measures the company's stock value relative to its cash flow, and is sometimes said to be a more objective measure of a company's value because cash flows cannot be manipulated as easily as earnings, which considers non-cash items such as depreciation and amortization. SIDO's P/CF ratio of 18.90x is considered a relatively high ratio by analysts.

Low
The Enterprise Value/Revenue ratio (EV/R) is calculated by dividing the enterprise value of a company by its revenue. It measures the company's enterprise value relative to its revenue. It is an indicator of how much it costs to buy the company's revenue; the lower the ratio, the cheaper the company's revenue. SIDO's EV/R ratio of 5.36x is considered a relatively high ratio The average EV/R ratio for the Pharmaceuticals & Health Care Research sector is 1.40x.

Medium
Fairly Close to Intrinsic Value: Analyst's intrinsic value is of SIDO is IDR 653.68, which is 1% lower than SIDO's last closing price of IDR 665.00.

Peers

SIDO Peers and Comparison

Market Cap.

Peer Companies

Supertype Fuzzy Search
SymbolCompany Name
Market Cap
(in Trillion IDR)
Total Assets
(in Trillion IDR)
Total Revenue
(in Trillion IDR)
Profit and Loss
(in Trillion IDR)
P/E
P/B
KLBFKalbe Farma Tbk65.45T27.06T 30.45T 2.77T 23.663.06
MIKAPT Mitra Keluarga Karyasehat Tbk.36.85T7.34T 4.26T 0.92T 40.236.33
SILOPT Siloam International Hospitals Tbk.31.10T10.98T 11.19T 1.21T 25.683.93
SRAJSejahteraraya Anugrahjaya Tbk20.58T5.61T 2.50T -0.04T -534.7211.09
SIDOPT Industri Jamu Dan Farmasi Sido Muncul Tbk19.95T3.89T 3.57T 0.95T 20.995.89
HEALPT Medikaloka Hermina Tbk.16.86T8.80T 5.78T 0.44T 38.544.36
PRAYPT Famon Awal Bros Sedaya Tbk9.56T4.70T 1.84T 0.22T 44.073.42
TSPCTempo Scan Pacific Tbk8.66T11.32T 13.12T 1.18T 7.351.12
SOHOPT Soho Global Health Tbk6.24T4.75T 8.20T 0.37T 16.822.60
OMEDPT Jayamas Medica Industri Tbk5.33T2.58T 1.74T 0.26T 20.552.40
Competitiveness Recap of SIDO stock
WeightNotesScore
High
At a market cap of IDR 19,950.00 billion, SIDO.JK ranks 5 in Market Cap out of 10 companies in the Healthcare sector.

High
At a PE of 20.99, SIDO.JK ranks 6 out of 10 companies in the Healthcare sector for P/E value. The average PE is -29.68 (unadjusted). A high P/E ratio often indicates higher growth expectation, or other qualitative factors that led investors to believe that the company has a defensible competitive advantage compared to its peers in Healthcare. In this regard, it trails behind sector leaders such as PT Famon Awal Bros Sedaya Tbk (44.07) in the Healthcare sector.

Medium
At a PE of 20.99, SIDO.JK is trading at a higher PE than that of its subsector peers in Pharmaceuticals & Health Care Research (median of 10.68). false

Medium
At a revenue of IDR 3.57 trillion, SIDO.JK ranks 7 in Revenue out of 10 companies in the Healthcare sector.

Medium
At a profit of IDR 0.95 trillion, SIDO.JK ranks 4 in Profit out of 10 companies in the Healthcare sector.

Future

Future Growth of SIDO

Growth Forecasts

SIDO 2024 Revenue Growth
+7.1%
SIDO 2024 EPS Growth
0.0%
Sector Revenue Growth
+7.1%
Pharmaceuticals & Health Care Research
Indonesia Market Growth
+7.6%
IDX overall growth
Pharmaceuticals & Health Care Research Sector Revenue Growth '24
-5.8%
Healthcare Sector Revenue Growth '24
-5.8%

Sector Benchmark

Pharmaceuticals & Health Care Research companies in Indonesia are growing at a projected rate of 7.12% against the IDX average of +7.6%.

Pharmaceuticals & Health Care Research sector overview

SIDO Earnings & Revenue Forecast

All values in IDR billion

Future growth prospect of SIDO
WeightNotesScore
High
SIDO's projected growth rate of 7.12% is below the ID market average of 7.62%.

High
The Pharmaceuticals & Health Care Research sub-sector is projected to shrink revenue by -5.79% in 2024. This number is higher than the previous year 2023's growth rate of -24.01%. false

Medium
The Pharmaceuticals & Health Care Research sub-sector is projected to decrease earnings by 0.00% in 2024. This number is lower than the previous year 2023's EPS growth of 0.00%. false

Medium
SIDO and its peers in the Pharmaceuticals & Health Care Research sub-sector belongs to the Healthcare sector. Companies in the Healthcare sector are projected to have a challenging year heading into 2024. Specifically, earnings are projected to decrease by 0.00% in 2024 while revenue growth is projected to decrease by -5.79%. These macroeconomic trends will likely be a headwind for SIDO's earnings growth prospects in the next 2 years.

Loading...
Loading...

Management

Executive Management

President Director

David Hidayat15.2 years
Irwan Hidayat
Director
Leonard
Director
Darmadji Sidik
Director
NamePositionShares%
Irwan HidayatDirector1,279,400< 0.01
Johan HidayatCommissioner1,857,068< 0.01
LeonardDirector1,313,550< 0.01
Expressed in millions IDR, unless otherwise stated

Ownership

SIDO Ownership

Others
18.72%
Insiders
77.61%
Institutions
3.67%
NameNumber of SharesOwnership (%)Value
Pt. Hotel Candi Baru18,137,404,58060.4612,061.37B
Public (Scripless)6,717,247,38822.394,466.97B
Concordant Investments Pte. Ltd.5,140,877,86217.143,418.68B
Johan Hidayat1,857,0680.011.23B
No data is available for SIDO at the moment.